Compare SDHC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDHC | EVO |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.9M | 778.3M |
| IPO Year | 2023 | 2007 |
| Metric | SDHC | EVO |
|---|---|---|
| Price | $14.12 | $1.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $14.60 | $7.00 |
| AVG Volume (30 Days) | 30.9K | ★ 45.9K |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $971,116,000.00 | N/A |
| Revenue This Year | $4.21 | $1.37 |
| Revenue Next Year | $11.07 | $10.05 |
| P/E Ratio | $155.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.72 | $1.90 |
| 52 Week High | $23.49 | $4.27 |
| Indicator | SDHC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.76 | 36.82 |
| Support Level | $14.04 | $1.90 |
| Resistance Level | $14.49 | $3.84 |
| Average True Range (ATR) | 0.74 | 0.05 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 37.16 | 8.20 |
Smith Douglas Homes Corpis a builder of single-family homes in communities in certain markets in the southeastern and southern United States. The Company's homes and communities are targeted to first-time and empty-nest homebuyers. The Company currently operates in metropolitan Atlanta, Birmingham, Chattanooga, Central Georgia, Charlotte, Dallas-Fort Worth, Greenville, Alabama Gulf Coast, Huntsville, Nashville, Raleigh and Houston. Its operations are currently organized into ten geographical divisions which comprise two reportable segments. Its Southeast segment consists of its Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of its Alabama, Dallas-Fort Worth, Houston, Nashville, and Alabama Gulf Coast divisions.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.